Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection.

We derive the Nash equilibrium strategies of the jammers and the malicious user and illustrate the effect of the transmission and jamming cost on the optimal strategy. Further, we observe that the ...